

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VII, LLC,
Petitioner,

v.

POZEN INC.,
Patent Owner.

Case IPR2015-01718
Patent 8,945,621

**PATENT OWNER POZEN INC.'S PATENT OWNER RESPONSE
PURSUANT TO 37 C.F.R. § 42.120**

TABLE OF CONTENTS

I. INTRODUCTION 1
 A. Background 1
 B. Relief Requested..... 1
 C. Related Proceedings 1
 D. Summary of Argument..... 2
II. RELEVANT LAW 6
III. RELEVANT TECHNICAL BACKGROUND 9
 A. NSAID-Induced Gastric Ulcers 9
 B. NSAIDs Taken Concurrently With LDA Pose an Increased Risk of Gastric Ulcer Compared to NSAIDs Taken Alone 13
 C. The Inventors of the '621 Patent Surprisingly Found that a Unit Dose Form of Immediate-Release Esomeprazole and Delayed-Release Naproxen is More Effective at Reducing NSAID-Associated Ulcers in Patients Taking LDA than in Patients Not Taking LDA 15
 D. The Prosecution History of the '621 Patent 18
IV. LEVEL OF SKILL IN THE ART 21
V. INTERPRETATIONS OF THE '621 PATENT CLAIMS 22
 A. “Low Dose Aspirin” and “LDA” 22
 B. “Unit Dosage Form” 22
VI. THE SCOPE AND CONTENT OF THE CITED ART 23
 A. Plachetka 23
 B. Graham 25
 C. Goldstein 26
VII. ARGUMENT 28
 A. The “Wherein” Clause is Entitled to Patentable Weight Because it was Added by the Examiner as a Condition for Allowance 29
 B. Claims 1-16 of the '621 Patent are Not Obvious Over Plachetka in View of Graham and Goldstein..... 33

1.	The Data from Graham and Goldstein Does Not Support a Conclusion as to the Effect of Taking Concomitant LDA with an Acid Inhibitor and an NSAID	36
2.	Dr. Shargel Uses Flawed Data from Goldstein that Render His Calculations Meaningless	40
3.	A POSA Would Not Have Expected that Administering a Unit Dose Form of Immediate-Release Esomeprazole and Delayed-Release Naproxen is More Effective at Reducing NSAID-Associated Ulcers in Patients Taking LDA than in Patients Not Taking LDA	43
C.	Claims 1-16 of the '621 Patent are Not Obvious Over Plachetka	46
1.	Plachetka Does Not Inherently Teach that “Administration of the Unit Dose Form is More Effective at Reducing the Incidence of the NSAID-Associated Ulcers in Patients Taking LDA than in Patients Not Taking LDA who are Administered the Unit Dose Form”	47
2.	A POSA Would Have Had No Expectation of Success in Administering a Unit Dose Form of Immediate-Release Esomeprazole and Delayed-Release Naproxen that is More Effective at Reducing NSAID-Associated Ulcers in Patients Taking LDA than in Patients Not Taking LDA	50
D.	Even if the Final “Wherein” Clause is Not Afforded Patentable Weight, the Challenged Claims are Not Obvious Due to Surprising and Unexpected Results	51
VIII.	CONCLUSION.....	55

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>Allergan, Inc. v. Sandoz Inc.</i> , 726 F.3d 1286 (Fed. Cir. 2013)	49
<i>Biosig Instruments, Inc. v. Nautilus, Inc.</i> , 783 F.3d 1374 (Fed. Cir. 2015)	31
<i>Biosig Instruments, Inc. v. Nautilus, Inc.</i> , 715 F.3d 891 (Fed. Cir. 2013), vacated and remanded on other grounds, 134, S. Ct. 2120 (2014)	32
<i>Crocs, Inc. v. Int’l Trade Comm’n</i> , 598 F.3d 1294 (Fed. Cir. 2010)	52
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.</i> , 676 F.3d 1063 (Fed. Cir. 2012)	6
<i>Eltech Sys. Corp. v. PPG Indus., Inc.</i> , 710 F. Supp. 622 (W.D. La. 1988) <i>aff’d</i> , 903 F.2d 805 (Fed. Cir. 1990)	32
<i>Graham v. John Deere Co. of Kansas City</i> , 383 U.S. 1 (1966)	7
<i>Hoffer v. Microsoft Corp.</i> , 405 F.3d 1326 (Fed. Cir. 2005) (per curiam)	31
<i>In re Huai-Hung Kao</i> , 639 F.3d 1057 (Fed. Cir. 2011)	52
<i>Intelligent Bio-Sys., Inc. v. Illumina Cambridge Ltd.</i> , No. 2015-1693, 2016 WL 2620512 (Fed. Cir. May 9, 2016)	7
<i>KSR Int’l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007)	6

<i>Minton v. Nat’l Ass’n of Sec. Dealers, Inc.</i> , 336 F.3d 1373 (Fed. Cir. 2003)	30, 31
<i>Nike, Inc. v. Adidas AG</i> , 812 F.3d 1326 (Fed. Cir. 2016)	7
<i>Numatics, Inc. v. Balluff, Inc.</i> , 66 F. Supp. 3d 934, 941 (E.D. Mich. 2014)	43
<i>In re Oelrich</i> , 666 F.2d 578 (C.C.P.A. 1981)	8, 48, 49
<i>Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc.</i> , 520 F.3d 1358 (Fed. Cir. 2008)	52
<i>Panduit Corp. v. Dennison Mfg. Co.</i> , 810 F.2d 1561 (Fed. Cir. 1987)	7
<i>PAR Pharm., Inc. v. TWI Pharm., Inc.</i> , 773 F.3d 1186 (Fed. Cir. 2014)	6, 8, 48, 49
<i>Research Found. of State Univ. of New York v. Mylan Pharm. Inc.</i> , 723 F. Supp. 2d 638 (D. Del. 2010).....	31
<i>Ricoh Co., Ltd. v. Quanta Computer Inc.</i> , 550 F.3d 1325 (Fed. Cir. 2008)	8
<i>Stratoflex, Inc. v. Aeroquip Corp.</i> , 713 F.2d 1530 (Fed. Cir. 1983)	52
<i>Texas Instruments Inc. v. U.S. Int’l Trade Comm’n</i> , 988 F.2d 1165 (Fed. Cir. 1993)	30
<i>Thermalloy Inc. v. Aavid Eng’g, Inc.</i> , 935 F. Supp. 55 (D.N.H. 1996), amended by, 935 F. Supp. 63 (D.N.H. 1996), <i>aff’d</i> , 121 F.3d 691 (Fed. Cir. 1997)	32
<i>Transocean Offshore Deepwater Drilling, Inc. v. Maersk Drilling USA, Inc.</i> , 699 F.3d 1340 (Fed. Cir. 2012)	7
<i>Unigene Labs, Inc. v. Apotex, Inc.</i> , 655 F.3d 1352 (Fed. Cir. 2011)	7

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.